Table 4.
Profile of antiphospholipid antibodies in patients with APS or healthy controls.
| Total positivity | ||||||||
|---|---|---|---|---|---|---|---|---|
| APS | Healthy controls (n=120) | χ12 | P1 | χ22 | P2 | |||
| Total (n=212) | PAPS (n = 153) | SAPS (n = 59) | ||||||
| aCL | 118 (55.66%) | 72 (47.06%) | 46 (77.97%) | 3 (2.5%) | 93.49 | <0.001 | 16.481 | <0.001 |
| IgA–aCL | 33 (15.57%) | 18 (11.76%) | 15 (25.42%) | 0 | 20.741 | <0.001 | 6.044 | 0.020 |
| IgG–aCL | 106 (50%) | 64 (41.83%) | 42 (71.19%) | 1 (0.83%) | 84.807 | <0.001 | 14.678 | <0.001 |
| IgM–aCL | 19 (8.96%) | 10 (6.54%) | 9 (15.25%) | 2 (1.67%) | 6.883 | 0.009 | 3.967 | 0.060 |
| aβ2GPI | 122 (57.55%) | 79 (51.64%) | 43 (72.88%) | 5 (4.17%) | 92.441 | <0.001 | 7.868 | 0.005 |
| IgA–aβ2GPⅠ | 28 (13.21%) | 16 (10.46%) | 12 (20.34%) | 0 | 17.309 | <0.001 | 3.627 | 0.070 |
| IgG–aβ2GPⅠ | 90 (42.45%) | 56 (36.60%) | 34 (57.63%) | 0 | 69.889 | <0.001 | 7.705 | 0.008 |
| IgM–aβ2GPⅠ | 57 (26.89%) | 33 (21.57%) | 24 (40.68%) | 5 (4.17%) | 26.045 | <0.001 | 7.910 | 0.006 |
| Isolated positivity | ||||||||
| aCL | ||||||||
| IgA–aCL | 4 (1.89%) | 3 (1.96%) | 1 (1.70%) | 0 | 2.292 | 0.130 | 0.016 | 0.899 |
| IgG–aCL | 72 (33.96%) | 45 (29.41%) | 27 (45.76%) | 1 (0.83%) | 49.028 | <0.001 | 5.076 | 0.035 |
| IgM–aCL | 7 (3.3%) | 5 (3.27%) | 2 (3.39%) | 2 (1.67%) | 0.777 | 0.378 | 0.002 | 0.965 |
| aβ2GPI | ||||||||
| IgA–aβ2GPⅠ | 1 (0.47%) | 1 (0.65%) | 0 | 0 | 0.658 | 0.451 | 0.387 | 0.534 |
| IgG–aβ2GPⅠ | 45 (21.23%) | 34 (22.22%) | 11 (18.64%) | 0 | 29.466 | <0.001 | 0.326 | 0.583 |
| IgM–aβ2GPⅠ | 28 (13.21%) | 20 (13.07%) | 8 (13.56%) | 5 (4.17%) | 6.997 | 0.008 | 0.009 | 0.925 |
P1, APS vs. HC; P2, PAPS vs. SAPS.